BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29-37. [PMID: 12831921 DOI: 10.1016/s1072-7515(03)00230-8] [Cited by in Crossref: 519] [Cited by in F6Publishing: 155] [Article Influence: 28.8] [Reference Citation Analysis]
Number Citing Articles
1 Goretzki PE, Starke A, Akca A, Lammers BJ. Surgery for neuroendocrine tumors of the gastroenteropancreatic system (GEP-NET). Internist (Berl). 2012;53:152-160. [PMID: 22290318 DOI: 10.1007/s00108-011-2917-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
2 Hüttner FJ, Schneider L, Tarantino I, Warschkow R, Schmied BM, Hackert T, Diener MK, Büchler MW, Ulrich A. Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis. Langenbecks Arch Surg. 2015;400:715-723. [PMID: 26198970 DOI: 10.1007/s00423-015-1323-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
3 Heinrich S, Watzka F, Lang H. Integrative Concepts for Liver Surgery. Visc Med 2020;36:351-8. [PMID: 33178731 DOI: 10.1159/000511043] [Reference Citation Analysis]
4 Wu J, Sun C, Li E, Wang J, He X, Yuan R, Yi C, Liao W, Wu L. Non-functional pancreatic neuroendocrine tumours: emerging trends in incidence and mortality. BMC Cancer 2019;19:334. [PMID: 30961556 DOI: 10.1186/s12885-019-5543-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
5 Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med 2018;59:66-74. [PMID: 29025982 DOI: 10.2967/jnumed.117.202275] [Cited by in Crossref: 99] [Cited by in F6Publishing: 81] [Article Influence: 24.8] [Reference Citation Analysis]
6 Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727-1733. [PMID: 18515795 DOI: 10.1093/annonc/mdn351] [Cited by in Crossref: 473] [Cited by in F6Publishing: 410] [Article Influence: 36.4] [Reference Citation Analysis]
7 Eto K, Yoshida N, Iwagami S, Iwatsuki M, Baba H. Surgical treatment for gastrointestinal neuroendocrine tumors. Ann Gastroenterol Surg 2020;4:652-9. [PMID: 33319155 DOI: 10.1002/ags3.12396] [Reference Citation Analysis]
8 Machairas N, Daskalakis K, Felekouras E, Alexandraki KI, Kaltsas G, Sotiropoulos GC. Currently available treatment options for neuroendocrine liver metastases. Ann Gastroenterol 2021;34:130-41. [PMID: 33654350 DOI: 10.20524/aog.2021.0574] [Reference Citation Analysis]
9 Spolverato G, Bagante F, Aldrighetti L, Poultsides G, Bauer TW, Field RC, Marques HP, Weiss M, Maithel SK, Pawlik TM. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery. J Gastrointest Surg 2017;21:2039-47. [PMID: 28744737 DOI: 10.1007/s11605-017-3491-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
10 Maxwell JE, Sherman SK, Howe JR. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors. Clin Cancer Res 2016;22:5022-9. [PMID: 27742788 DOI: 10.1158/1078-0432.CCR-16-0435] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
11 Maekawa A, Kudo A, Kishino M, Murase Y, Watanabe S, Ishikawa Y, Ueda H, Akahoshi K, Ogawa K, Ono H, Tanaka S, Kinowaki Y, Tanabe M. Hormonal tumor mapping for liver metastases of gastroenteropancreatic neuroendocrine neoplasms: a novel therapeutic strategy. J Cancer Res Clin Oncol 2021. [PMID: 33904982 DOI: 10.1007/s00432-021-03650-2] [Reference Citation Analysis]
12 Maxwell JE, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy? Surgery. 2016;159:320-333. [PMID: 26454679 DOI: 10.1016/j.surg.2015.05.040] [Cited by in Crossref: 86] [Cited by in F6Publishing: 69] [Article Influence: 14.3] [Reference Citation Analysis]
13 Abutaka A, El-Matbouly M, Helmy I, Elmoghazy W, Sulieman I, Ben Gashir M, Soofi M, Khalaf H, Elaffandi A. Repeat liver resection for pure large cell neuroendocrine carcinoma of the gallbladder: a favorable outcome. World J Surg Oncol 2019;17:126. [PMID: 31325969 DOI: 10.1186/s12957-019-1666-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Cavalcoli F, Rausa E, Conte D, Nicolini AF, Massironi S. Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies? World J Gastroenterol 2017; 23(15): 2640-2650 [PMID: 28487601 DOI: 10.3748/wjg.v23.i15.2640] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
15 Callahan AF, White M, Ituarte P, Gagandeep S, Woo Y, Fong Y, Melstrom L. Surgical Intervention in Gastric Carcinoid is Associated With Improved Survival in Local and Regional Disease. Am J Clin Oncol 2018;41:882-7. [PMID: 28763328 DOI: 10.1097/COC.0000000000000392] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Gundara JS, Alvarado-Bachmann R, Williams N, Gananadha S, Gill A, Hugh TJ, Samra JS. Multivisceral resection of pancreatic neuroendocrine tumours: a report of two cases. World J Surg Oncol 2011;9:93. [PMID: 21859472 DOI: 10.1186/1477-7819-9-93] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Kerkar SP, Kemp CD, Avital I. Liver resections in metastatic gastric cancer. HPB (Oxford) 2010;12:589-96. [PMID: 20961366 DOI: 10.1111/j.1477-2574.2010.00224.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
18 House MG, Cameron JL, Lillemoe KD, Schulick RD, Choti MA, Hansel DE, Hruban RH, Maitra A, Yeo CJ. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg. 2006;10:138-145. [PMID: 16368504 DOI: 10.1016/j.gassur.2005.05.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
19 Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo). 2018;73:e490s. [PMID: 30133565 DOI: 10.6061/clinics/2018/e490s] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
20 Gomez D, Malik HZ, Al-Mukthar A, Menon KV, Toogood GJ, Lodge JP, Prasad KR. Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB (Oxford) 2007;9:345-51. [PMID: 18345317 DOI: 10.1080/13651820701504199] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
21 Alistar A, Sung M, Kim M, Holcombe RF. Clinical pathways for pancreatic neuroendocrine tumors. J Gastrointest Cancer 2012;43:532-40. [PMID: 22661335 DOI: 10.1007/s12029-012-9397-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
22 Zhao ZM, Wang J, Ugwuowo UC, Wang L, Townsend JP. Primary hepatic neuroendocrine carcinoma: report of two cases and literature review. BMC Clin Pathol 2018;18:3. [PMID: 29507528 DOI: 10.1186/s12907-018-0070-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
23 Musholt TJ. [Extent of resection for neuroendocrine tumors of the small intestine]. Chirurg 2011;82:591-7. [PMID: 21678105 DOI: 10.1007/s00104-011-2070-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
24 Scott AT, Howe JR. Evaluation and Management of Neuroendocrine Tumors of the Pancreas. Surg Clin North Am 2019;99:793-814. [PMID: 31255207 DOI: 10.1016/j.suc.2019.04.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
25 Gaujoux S, Sauvanet A, Belghiti J. Place of surgical resection in the treatment strategy of gastrointestinal neuroendocrine tumors. Target Oncol 2012;7:153-9. [PMID: 22923166 DOI: 10.1007/s11523-012-0230-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
26 Liu EH, Solorzano CC, Katznelson L, Vinik AI, Wong R, Randolph G. AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocr Pract. 2015;21:534-545. [PMID: 25962092 DOI: 10.4158/ep14464.dsc] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
27 Shao QQ, Zhao BB, Dong LB, Cao HT, Wang WB. Surgical management of Zollinger-Ellison syndrome: Classical considerations and current controversies. World J Gastroenterol 2019; 25(32): 4673-4681 [PMID: 31528093 DOI: 10.3748/wjg.v25.i32.4673] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Wong KP, Tsang JS, Lang BH. Role of surgery in pancreatic neuroendocrine tumor. Gland Surg 2018;7:36-41. [PMID: 29629318 DOI: 10.21037/gs.2017.12.05] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
29 Katz SC, Donkor C, Glasgow K, Pillarisetty VG, Gönen M, Espat NJ, Klimstra DS, D'Angelica MI, Allen PJ, Jarnagin W, Dematteo RP, Brennan MF, Tang LH. T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases. HPB (Oxford) 2010;12:674-83. [PMID: 21083792 DOI: 10.1111/j.1477-2574.2010.00231.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
30 Shankar N, Linzay C, Rowe K. Vasoactive intestinal peptide-oma causing refractory diarrhea in a young woman. Proc (Bayl Univ Med Cent). 2020;33:641-643. [PMID: 33100555 DOI: 10.1080/08998280.2020.1778963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Pan M, Yang Y, Teng T, Lu F, Chen Y, Huang H. Development and validation of a simple-to-use nomogram to predict liver metastasis in patients with pancreatic neuroendocrine neoplasms: a large cohort study. BMC Gastroenterol 2021;21:101. [PMID: 33663420 DOI: 10.1186/s12876-021-01685-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH. Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci 2006;51:877-84. [PMID: 16758309 DOI: 10.1007/s10620-006-9345-4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 3.1] [Reference Citation Analysis]
33 Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776-783; discussion 783-785. [PMID: 15849513 DOI: 10.1097/01.sla.0000161981.58631.ab] [Cited by in Crossref: 250] [Cited by in F6Publishing: 213] [Article Influence: 15.6] [Reference Citation Analysis]
34 Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017;46:715-731. [PMID: 28609357 DOI: 10.1097/mpa.0000000000000846] [Cited by in Crossref: 127] [Cited by in F6Publishing: 57] [Article Influence: 42.3] [Reference Citation Analysis]
35 Zerbi A, Capitanio V, Boninsegna L, Delle Fave G, Pasquali C, Rindi G, Campana D, Falconi M; AISP-Network Study Group. Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. HPB (Oxford) 2013;15:935-43. [PMID: 23472667 DOI: 10.1111/hpb.12065] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
36 Thiels CA, Bergquist JR, Laan DV, Croome KP, Smoot RL, Nagorney DM, Thompson GB, Kendrick ML, Farnell MB, Truty MJ. Outcomes of Pancreaticoduodenectomy for Pancreatic Neuroendocrine Tumors: Are Combined Procedures Justified? J Gastrointest Surg. 2016;20:891-898. [PMID: 26925796 DOI: 10.1007/s11605-016-3102-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
37 Gurusamy KS, Ramamoorthy R, Sharma D, Davidson BR. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev. 2009;CD007060. [PMID: 19370671 DOI: 10.1002/14651858.cd007060.pub2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
38 Fendrich V, Bartsch DK. Surgical treatment of gastrointestinal neuroendocrine tumors. Langenbecks Arch Surg. 2011;396:299-311. [PMID: 21279821 DOI: 10.1007/s00423-011-0741-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
39 Lee SY, Cheow PC, Teo JY, Ooi LL. Surgical treatment of neuroendocrine liver metastases. Int J Hepatol 2012;2012:146590. [PMID: 22319650 DOI: 10.1155/2012/146590] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
40 Kose E, Kahramangil B, Aydin H, Donmez M, Takahashi H, Aucejo F, Siperstein A, Berber E. Outcomes of laparoscopic tumor ablation for neuroendocrine liver metastases: a 20-year experience. Surg Endosc. 2020;34:249-256. [PMID: 30945061 DOI: 10.1007/s00464-019-06759-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
41 Gurusamy KS, Pamecha V, Sharma D, Davidson BR. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev 2009;:CD007118. [PMID: 19160322 DOI: 10.1002/14651858.CD007118.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
42 Chan MY, Ma KW, Chan A. Surgical management of neuroendocrine tumor-associated liver metastases: a review. Gland Surg 2018;7:28-35. [PMID: 29629317 DOI: 10.21037/gs.2017.11.16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
43 Larouche V, Akirov A, Alshehri S, Ezzat S. Management of Small Bowel Neuroendocrine Tumors. Cancers (Basel) 2019;11:E1395. [PMID: 31540509 DOI: 10.3390/cancers11091395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
44 Kawaguchi Y, De Bellis M, Panettieri E, Duwe G, Vauthey JN. Debate: Improvements in Systemic Therapies for Liver Metastases Will Increase the Role of Locoregional Treatments. Surg Oncol Clin N Am 2021;30:205-18. [PMID: 33220806 DOI: 10.1016/j.soc.2020.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Zerbi A, Capitanio V, Boninsegna L, Pasquali C, Rindi G, Delle Fave G, Del Chiaro M, Casadei R, Falconi M. Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases. Langenbecks Arch Surg. 2011;396:313-321. [PMID: 20857140 DOI: 10.1007/s00423-010-0712-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
46 Schiergens TS, Lüning J, Renz BW, Thomas M, Pratschke S, Feng H, Lee SM, Engel J, Rentsch M, Guba M. Liver Resection for Non-colorectal Non-neuroendocrine Metastases: Where Do We Stand Today Compared to Colorectal Cancer? J Gastrointest Surg. 2016;20:1163-1172. [PMID: 26921025 DOI: 10.1007/s11605-016-3115-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
47 Bacchetti S, Bertozzi S, Londero AP, Uzzau A, Pasqual EM. Surgical treatment and survival in patients with liver metastases from neuroendocrine tumors: a meta-analysis of observational studies. Int J Hepatol. 2013;2013:235040. [PMID: 23509630 DOI: 10.1155/2013/235040] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
48 Johnston ME 2nd, Carter MM, Wilson GC, Ahmad SA, Patel SH. Surgical management of primary pancreatic neuroendocrine tumors. J Gastrointest Oncol 2020;11:578-89. [PMID: 32655937 DOI: 10.21037/jgo.2019.12.09] [Reference Citation Analysis]
49 Lu F, Poruk KE, Weiss MJ. Surgery for oligometastasis of pancreatic cancer. Chin J Cancer Res. 2015;27:358-367. [PMID: 26361405 DOI: 10.3978/j.issn.1000-9604.2015.05.02] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
50 Hanazaki K, Sakurai A, Munekage M, Ichikawa K, Namikawa T, Okabayashi T, Imamura M. Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1. Surg Today. 2013;43:229-236. [PMID: 23076685 DOI: 10.1007/s00595-012-0376-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
51 Singh PP, Malhotra AS, Kashyap V. Carcinoid tumor of the kidney: An unusual renal tumor. Indian J Urol 2009;25:537-8. [PMID: 19955684 DOI: 10.4103/0970-1591.57921] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
52 Coe SG, Tan WW, Fox TP. Cushing's syndrome due to ectopic adrenocorticotropic hormone production secondary to hepatic carcinoid: diagnosis, treatment, and improved quality of life. J Gen Intern Med 2008;23:875-8. [PMID: 18386102 DOI: 10.1007/s11606-008-0587-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
53 Pourmand K, Itzkowitz SH. Small Bowel Neoplasms and Polyps. Curr Gastroenterol Rep 2016;18:23. [PMID: 27086004 DOI: 10.1007/s11894-016-0497-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
54 Gedaly R, Jeon H, Johnston TD, McHugh PP, Rowland RG, Ranjan D. Surgical treatment of a rare primary renal carcinoid tumor with liver metastasis. World J Surg Oncol 2008;6:41. [PMID: 18430248 DOI: 10.1186/1477-7819-6-41] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
55 Srirajaskanthan R, Ahmed A, Prachialias A, Srinivasan P, Heaton N, Jervis N, Quaglia A, Vivian G, Ramage JK. ENETS TNM staging predicts prognosis in small bowel neuroendocrine tumours. ISRN Oncol. 2013;2013:420795. [PMID: 23533809 DOI: 10.1155/2013/420795] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
56 Alagusundaramoorthy SS, Gedaly R. Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor. World J Gastroenterol 2014; 20(39): 14348-14358 [PMID: 25339822 DOI: 10.3748/wjg.v20.i39.14348] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
57 Pitt SC, Knuth J, Keily JM, McDermott JC, Weber SM, Chen H, Rilling WS, Quebbeman EJ, Agarwal DM, Pitt HA. Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg. 2008;12:1951-1960. [PMID: 18709512 DOI: 10.1007/s11605-008-0640-6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 5.8] [Reference Citation Analysis]
58 Basuroy R, Srirajaskanthan R, Ramage JK. A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol 2012;2012:819193. [PMID: 22518323 DOI: 10.1155/2012/819193] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
59 Sherman SK, Maxwell JE, O'Dorisio MS, O'Dorisio TM, Howe JR. Pancreastatin predicts survival in neuroendocrine tumors. Ann Surg Oncol 2014;21:2971-80. [PMID: 24752611 DOI: 10.1245/s10434-014-3728-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
60 Scott AT, Breheny PJ, Keck KJ, Bellizzi AM, Dillon JS, O'Dorisio TM, Howe JR. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery. 2019;165:166-175. [PMID: 30343949 DOI: 10.1016/j.surg.2018.04.070] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
61 Sim DPY, Goh BKP, Lee SY, Chan CY, Tan IBH, Cheow PC, Jeyaraj P, Chow PKH, Ooi LLPJ, Chung AYF. Preoperative Prognostic Factors After Liver Resection for Non-Colorectal, Non-Neuroendocrine Liver Metastases and Validation of the Adam Score in an Asian Population. World J Surg 2018;42:1073-84. [PMID: 28875334 DOI: 10.1007/s00268-017-4208-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
62 Ichida H, Imamura H, Yoshimoto J, Sugo H, Kajiyama Y, Tsurumaru M, Suzuki K, Ishizaki Y, Kawasaki S. Pattern of Postoperative Recurrence and Hepatic and/or Pulmonary Resection for Liver and/or Lung Metastases From Esophageal Carcinoma. World J Surg 2013;37:398-407. [DOI: 10.1007/s00268-012-1830-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
63 Cheung TT, Chok KS, Chan AC, Tsang S, Dai JW, Lang BH, Yau T, Chan SC, Poon RT, Fan ST, Lo CM. Long term survival analysis of hepatectomy for neuroendocrine tumour liver metastases. ScientificWorldJournal 2014;2014:524045. [PMID: 24526905 DOI: 10.1155/2014/524045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
64 Wu L, Fu J, Wan L, Pan J, Lai S, Zhong J, Chung DC, Wang L. Survival outcomes and surgical intervention of small intestinal neuroendocrine tumors: a population based retrospective study. Oncotarget. 2017;8:4935-4947. [PMID: 27903960 DOI: 10.18632/oncotarget.13632] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
65 Marudanayagam R, Sandhu B, Perera MT, Taniere P, Coldham C, Bramhall S, Mayer D, Buckels J, Mirza D. Hepatic resection for non-colorectal, non-neuroendocrine, non-sarcoma metastasis: a single-centre experience. HPB (Oxford) 2011;13:286-92. [PMID: 21418135 DOI: 10.1111/j.1477-2574.2010.00285.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
66 D’Haese JG, Tosolini C, Ceyhan GO, Kong B, Esposito I, Michalski CW, Kleeff J. Update on surgical treatment of pancreatic neuroendocrine neoplasms. World J Gastroenterol 2014; 20(38): 13893-13898 [PMID: 25320524 DOI: 10.3748/wjg.v20.i38.13893] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
67 Reidy-Lagunes D, Thornton R. Pancreatic neuroendocrine and carcinoid tumors: what’s new, what’s old, and what’s different? Curr Oncol Rep. 2012;14:249-256. [PMID: 22434313 DOI: 10.1007/s11912-012-0232-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
68 Keck KJ, Maxwell JE, Menda Y, Bellizzi A, Dillon J, O'Dorisio TM, Howe JR. Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors. Surgery 2017;161:272-9. [PMID: 27863780 DOI: 10.1016/j.surg.2016.05.055] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
69 Clift AK, Frilling A. Management of patients with hepatic metastases from neuroendocrine tumors. Ann Saudi Med. 2014;34:279-290. [PMID: 25811199 DOI: 10.5144/0256-4947.2014.279] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
70 Paiella S, Impellizzeri H, Zanolin E, Marchegiani G, Miotto M, Malpaga A, De Robertis R, D'Onofrio M, Rusev B, Capelli P, Cingarlini S, Butturini G, Davì MV, Amodio A, Bassi C, Scarpa A, Salvia R, Landoni L. Comparison of imaging-based and pathological dimensions in pancreatic neuroendocrine tumors. World J Gastroenterol 2017; 23(17): 3092-3098 [PMID: 28533666 DOI: 10.3748/wjg.v23.i17.3092] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
71 Lee E, Leon Pachter H, Sarpel U. Hepatic arterial embolization for the treatment of metastatic neuroendocrine tumors. Int J Hepatol. 2012;2012:471203. [PMID: 22319651 DOI: 10.1155/2012/471203] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
72 Konishi T, Watanabe T, Kishimoto J, Kotake K, Muto T, Nagawa H; Japanese Society for Cancer of the Colon and Rectum. Prognosis and risk factors of metastasis in colorectal carcinoids: results of a nationwide registry over 15 years. Gut. 2007;56:863-868. [PMID: 17213340 DOI: 10.1136/gut.2006.109157] [Cited by in Crossref: 149] [Cited by in F6Publishing: 124] [Article Influence: 10.6] [Reference Citation Analysis]
73 Nigri G, Petrucciani N, Debs T, Mangogna LM, Crovetto A, Moschetta G, Persechino R, Aurello P, Ramacciato G. Treatment options for PNET liver metastases: a systematic review. World J Surg Oncol. 2018;16:142. [PMID: 30007406 DOI: 10.1186/s12957-018-1446-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
74 Haugvik SP, Labori KJ, Edwin B, Mathisen Ø, Gladhaug IP. Surgical treatment of sporadic pancreatic neuroendocrine tumors: a state of the art review. ScientificWorldJournal. 2012;2012:357475. [PMID: 23304085 DOI: 10.1100/2012/357475] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
75 Yu X, Gu J, Wu H, Fu D, Li J, Jin C. Resection of Liver Metastases: A Treatment Provides a Long-Term Survival Benefit for Patients with Advanced Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. J Oncol. 2018;2018:6273947. [PMID: 30538745 DOI: 10.1155/2018/6273947] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
76 Tran CG, Sherman SK, Howe JR. Small Bowel Neuroendocrine Tumors. Curr Probl Surg 2020;57:100823. [PMID: 33234227 DOI: 10.1016/j.cpsurg.2020.100823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
77 Fendrich V, Michl P, Habbe N, Bartsch DK. Liver-specific therapies for metastases of neuroendocrine pancreatic tumors. World J Hepatol 2010; 2(10): 367-373 [PMID: 21160945 DOI: 10.4254/wjh.v2.i10.367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
78 Lewis MA, Hubbard J. Multimodal liver-directed management of neuroendocrine hepatic metastases. Int J Hepatol. 2011;2011:452343. [PMID: 22121491 DOI: 10.4061/2011/452343] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
79 Tsim NC, Frampton AE, Habib NA, Jiao LR. Surgical treatment for liver cancer. World J Gastroenterol 2010; 16(8): 927-933 [PMID: 20180230 DOI: 10.3748/wjg.v16.i8.927] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
80 Zheng M, Li Y, Li T, Zhang L, Zhou L. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis. Cancer Med 2019;8:5128-36. [PMID: 31328428 DOI: 10.1002/cam4.2431] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
81 Grandhi MS, Lafaro KJ, Pawlik TM. Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. J Gastrointest Surg. 2015;19:2273-2282. [PMID: 26341823 DOI: 10.1007/s11605-015-2931-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
82 Dermine S, Palmieri LJ, Lavolé J, Barré A, Dohan A, Abou Ali E, Cottereau AS, Gaujoux S, Brezault C, Chaussade S, Coriat R. Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors.J Clin Med. 2019;8. [PMID: 31703375 DOI: 10.3390/jcm8111907] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
83 Atema JJ, Jilesen AP, Busch OR, van Gulik TM, Gouma DJ, Nieveen van Dijkum EJ. Pancreatic fistulae after pancreatic resections for neuroendocrine tumours compared with resections for other lesions. HPB (Oxford). 2015;17:38-45. [PMID: 25041879 DOI: 10.1111/hpb.12319] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
84 Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol. 2011;4:29. [PMID: 21672194 DOI: 10.1186/1756-8722-4-29] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
85 McKenna LR, Edil BH. Update on pancreatic neuroendocrine tumors. Gland Surg. 2014;3:258-275. [PMID: 25493258 DOI: 10.3978/j.issn.2227-684x.2014.06.03] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
86 Cidon EU. New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World J Gastrointest Oncol 2017; 9(1): 4-20 [PMID: 28144395 DOI: 10.4251/wjgo.v9.i1.4] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
87 Tran CG, Sherman SK, Chandrasekharan C, Howe JR. Surgical Management of Neuroendocrine Tumor Liver Metastases. Surg Oncol Clin N Am 2021;30:39-55. [PMID: 33220808 DOI: 10.1016/j.soc.2020.08.001] [Reference Citation Analysis]
88 Musholt TJ, Lang H. [Indications and operative procedures for neuroendocrine liver metastases]. Chirurg 2009;80:113-21. [PMID: 19212693 DOI: 10.1007/s00104-008-1614-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
89 Deguelte S, Perrier M, Hammoutene C, Cadiot G, Kianmanesh R. Surgery and Perioperative Management in Small Intestinal Neuroendocrine Tumors. J Clin Med. 2020;9. [PMID: 32708330 DOI: 10.3390/jcm9072319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
90 Lowery AJ, Walsh S, McDermott EW, Prichard RS. Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas. Oncologist. 2013;18:391-407. [PMID: 23576482 DOI: 10.1634/theoncologist.2012-0410] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
91 Bacchetti S, Pasqual EM, Bertozzi S, Londero AP, Risaliti A. Curative versus palliative surgical resection of liver metastases in patients with neuroendocrine tumors: a meta-analysis of observational studies. Gland Surg. 2014;3:243-251. [PMID: 25493256 DOI: 10.3978/j.issn.2227-684x.2014.02.05] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
92 Raut CP, Kulke MH. Targeted therapy in advanced well-differentiated neuroendocrine tumors. Oncologist. 2011;16:286-295. [PMID: 21346024 DOI: 10.1634/theoncologist.2010-0313] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
93 Sherman SK, Maxwell JE, Carr JC, Wang D, Bellizzi AM, Sue O'Dorisio M, O'Dorisio TM, Howe JR. Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors. Clin Exp Metastasis 2014;31:935-44. [PMID: 25241033 DOI: 10.1007/s10585-014-9681-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
94 Paniccia A, Edil BH, Schulick RD. Pancreatic Neuroendocrine Tumors: an Update. Indian J Surg 2015;77:395-402. [PMID: 26722203 DOI: 10.1007/s12262-015-1360-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
95 Tran CG, Sherman SK, Howe JR. The Landmark Series: Management of Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 2021;28:2741-51. [PMID: 33452604 DOI: 10.1245/s10434-020-09566-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Rossi RE, Massironi S, Spampatti MP, Conte D, Ciafardini C, Cavalcoli F, Peracchi M. Treatment of liver metastases in patients with digestive neuroendocrine tumors. J Gastrointest Surg. 2012;16:1981-1992. [PMID: 22829240 DOI: 10.1007/s11605-012-1951-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
97 Strosberg JR, Weber JM, Choi J, Campos TL, Valone TL, Han G, Schell MJ, Kvols LK. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol. 2012;23:2335-2341. [PMID: 22317769 DOI: 10.1093/annonc/mdr614] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
98 Scoville SD, Xourafas D, Ejaz AM, Tsung A, Pawlik T, Cloyd JM. Contemporary indications for and outcomes of hepatic resection for neuroendocrine liver metastases. World J Gastrointest Surg 2020; 12(4): 159-170 [PMID: 32426095 DOI: 10.4240/wjgs.v12.i4.159] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
99 Pasqual EM, Bertozzi S, Londero AP, Bacchetti S, Lorenzin D, Pasqualucci A, Moccheggiani F, Federici A, Vivaverlli M, Risaliti A. Long term results of hepatic resection or orthotopic liver transplantation in patients with liver metastases from gastrointestinal neuroendocrine tumors. Oncol Lett 2016;12:3563-70. [PMID: 27900037 DOI: 10.3892/ol.2016.5045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
100 Du S, Wang Z, Sang X, Lu X, Zheng Y, Xu H, Xu Y, Chi T, Zhao H, Wang W, Cui Q, Zhong S, Huang J, Mao Y. Surgical resection improves the outcome of the patients with neuroendocrine tumor liver metastases: large data from Asia. Medicine (Baltimore) 2015;94:e388. [PMID: 25590842 DOI: 10.1097/MD.0000000000000388] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
101 Barreto SG, Shukla PJ, Shrikhande SV. Tumors of the Pancreatic Body and Tail. World J Oncol. 2010;1:52-65. [PMID: 29147182 DOI: 10.4021/wjon2010.04.200w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
102 Thomas RM, Truty MJ, Nogueras-Gonzalez GM, Fleming JB, Vauthey JN, Pisters PW, Lee JE, Rice DC, Hofstetter WL, Wolff RA. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg. 2012;16:1696-1704. [PMID: 22644446 DOI: 10.1007/s11605-012-1912-8] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 8.0] [Reference Citation Analysis]
103 Perrodin S, Lachenmayer A, Maurer M, Kim-Fuchs C, Candinas D, Banz V. Percutaneous stereotactic image-guided microwave ablation for malignant liver lesions. Sci Rep 2019;9:13836. [PMID: 31554853 DOI: 10.1038/s41598-019-50159-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
104 Eghtesad B, Aucejo F. Liver transplantation for malignancies. J Gastrointest Cancer. 2014;45:353-362. [PMID: 24604263 DOI: 10.1007/s12029-014-9590-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
105 Tsvetkova E, Sud S, Aucoin N, Biagi J, Burkes R, Samson B, Brule S, Cripps C, Colwell B, Falkson C, Dorreen M, Goel R, Halwani F, Maroun J, Michaud N, Tehfe M, Thirlwell M, Vickers M, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014. Curr Oncol 2015;22:e305-15. [PMID: 26300681 DOI: 10.3747/co.22.2603] [Reference Citation Analysis]
106 Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, Rothmund M. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg. 2006;244:845-851; discussion 852-853. [PMID: 17122609 DOI: 10.1097/01.sla.0000246951.21252.60] [Cited by in Crossref: 114] [Cited by in F6Publishing: 92] [Article Influence: 8.1] [Reference Citation Analysis]
107 Tierney JF, Poirier J, Chivukula S, Pappas SG, Hertl M, Schadde E, Keutgen X. Primary Tumor Site Affects Survival in Patients with Gastroenteropancreatic and Neuroendocrine Liver Metastases. Int J Endocrinol. 2019;2019:9871319. [PMID: 30992703 DOI: 10.1155/2019/9871319] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
108 Cloyd JM, Ejaz A, Konda B, Makary MS, Pawlik TM. Neuroendocrine liver metastases: a contemporary review of treatment strategies.Hepatobiliary Surg Nutr. 2020;9:440-451. [PMID: 32832495 DOI: 10.21037/hbsn.2020.04.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
109 Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117:268-275. [PMID: 20824724 DOI: 10.1002/cncr.25425] [Cited by in Crossref: 467] [Cited by in F6Publishing: 398] [Article Influence: 42.5] [Reference Citation Analysis]
110 Münstedt K, Franke FE. Role of primary surgery in advanced ovarian cancer. World J Surg Oncol 2004;2:32. [PMID: 15461788 DOI: 10.1186/1477-7819-2-32] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
111 Taner T, Atwell TD, Zhang L, Oberg TN, Harmsen WS, Slettedahl SW, Kendrick ML, Nagorney DM, Que FG. Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection. HPB (Oxford). 2013;15:190-195. [PMID: 23374359 DOI: 10.1111/j.1477-2574.2012.00528.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
112 Reidy DL, Tang LH, Saltz LB. Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nat Clin Pract Oncol. 2009;6:143-152. [PMID: 19190591 DOI: 10.1038/ncponc1326] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
113 Shah CP, Mramba LK, Bishnoi R, Unnikrishnan A, Duff JM, Chandana SR. Survival trends of metastatic small intestinal neuroendocrine tumor: a population-based analysis of SEER database. J Gastrointest Oncol 2019;10:869-77. [PMID: 31602324 DOI: 10.21037/jgo.2019.05.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
114 Neychev V, Kebebew E. Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature. Int J Surg Oncol 2017;2017:6424812. [PMID: 28593056 DOI: 10.1155/2017/6424812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
115 Landen S, Elens M, Vrancken C, Nuytens F, Meert T, Delugeau V. Giant hepatic carcinoid: a rare tumor with a favorable prognosis. Case Rep Surg. 2014;2014:456509. [PMID: 24653852 DOI: 10.1155/2014/456509] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
116 Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC; North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42:557-577. [PMID: 23591432 DOI: 10.1097/mpa.0b013e31828e34a4] [Cited by in Crossref: 326] [Cited by in F6Publishing: 141] [Article Influence: 40.8] [Reference Citation Analysis]
117 Fendrich V, Waldmann J, Bartsch DK, Langer P. Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol 2009;6:419-28. [DOI: 10.1038/nrclinonc.2009.82] [Cited by in Crossref: 81] [Cited by in F6Publishing: 62] [Article Influence: 6.8] [Reference Citation Analysis]
118 Shimura M, Mizuma M, Takadate T, Katoh Y, Suzuki T, Iseki M, Hata T, Aoki S, Suzuki Y, Sakata N, Ohtsuka H, Hayashi H, Morikawa T, Nakagawa K, Motoi F, Naitoh T, Igarashi K, Sasano H, Unno M. A novel liver metastasis-correlated protein of pancreatic neuroendocrine neoplasm (PanNEN) discovered by proteomic analysis. Oncotarget 2018;9:24291-303. [PMID: 29849941 DOI: 10.18632/oncotarget.25110] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
119 Norlén O, Daskalakis K, Öberg K, Åkerström G, Stålberg P, Hellman P. Indication for liver transplantation in young patients with small intestinal NETs is rare? World J Surg 2014;38:742-7. [PMID: 24233660 DOI: 10.1007/s00268-013-2331-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
120 Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ 2017;189:E398-404. [PMID: 28385820 DOI: 10.1503/cmaj.160771] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
121 Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135:1469-92. [PMID: 18703061 DOI: 10.1053/j.gastro.2008.05.047] [Cited by in Crossref: 479] [Cited by in F6Publishing: 388] [Article Influence: 36.8] [Reference Citation Analysis]
122 Sherman SK, Carr JC, Wang D, O'Dorisio MS, O'Dorisio TM, Howe JR. Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors. Surgery 2013;154:1206-13; discussion 1214. [PMID: 24238043 DOI: 10.1016/j.surg.2013.04.052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
123 Roland CL, Bian A, Mansour JC, Yopp AC, Balch GC, Sharma R, Xie XJ, Schwarz RE. Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes. J Surg Oncol 2012;105:595-600. [PMID: 22006521 DOI: 10.1002/jso.22118] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
124 Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plöckinger U. Multimodal management of neuroendocrine liver metastases. HPB (Oxford). 2010;12:361-379. [PMID: 20662787 DOI: 10.1111/j.1477-2574.2010.00175.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 78] [Article Influence: 9.4] [Reference Citation Analysis]
125 Shrikhande SV, Sirohi B, Goel M, Barreto SG. Pancreatic neuroendocrine tumors. Indian J Gastroenterol 2013;32:3-17. [PMID: 23054950 DOI: 10.1007/s12664-012-0257-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
126 Daskalakis K, Karakatsanis A, Hessman O, Stuart HC, Welin S, Tiensuu Janson E, Öberg K, Hellman P, Norlén O, Stålberg P. Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival. JAMA Oncol 2018;4:183-9. [PMID: 29049611 DOI: 10.1001/jamaoncol.2017.3326] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 18.5] [Reference Citation Analysis]
127 Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016;17:2191-2205. [PMID: 27635672 DOI: 10.1080/14656566.2016.1236916] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 6.2] [Reference Citation Analysis]
128 Lesurtel M, Nagorney DM, Mazzaferro V, Jensen RT, Poston GJ. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford). 2015;17:17-22. [PMID: 24636662 DOI: 10.1111/hpb.12225] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
129 Daskalakis K, Tsolakis AV. Upfront surgery of small intestinal neuroendocrine tumors. Time to reconsider? World J Gastroenterol 2018; 24(29): 3201-3203 [PMID: 30090001 DOI: 10.3748/wjg.v24.i29.3201] [Reference Citation Analysis]
130 Gut P. Liver metastases in gastroenteropancreatic neuroendocrine tumours - treatment methods. Prz Gastroenterol 2020;15:207-14. [PMID: 33005265 DOI: 10.5114/pg.2020.91501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
131 Yamamoto H, Hemmi H, Gu JY, Sekimoto M, Doki Y, Mori M. Minute liver metastases from a rectal carcinoid: A case report and review. World J Gastrointest Surg 2010; 2(3): 89-94 [PMID: 21160856 DOI: 10.4240/wjgs.v2.i3.89] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
132 Fiori S, Del Gobbo A, Gaudioso G, Caccamo L, Massironi S, Cavalcoli F, Bosari S, Ferrero S. Hepatic pseudocystic metastasis of well-differentiated ileal neuroendocrine tumor: a case report with review of the literature. Diagn Pathol 2013;8:148. [PMID: 24034980 DOI: 10.1186/1746-1596-8-148] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
133 Norton JA, Harris EJ, Chen Y, Visser BC, Poultsides GA, Kunz PC, Fisher GA, Jensen RT. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg. 2011;146:724-732. [PMID: 21690450 DOI: 10.1001/archsurg.2011.129] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 6.4] [Reference Citation Analysis]
134 Tsutsumi K, Ohtsuka T, Mori Y, Fujino M, Yasui T, Aishima S, Takahata S, Nakamura M, Ito T, Tanaka M. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. J Gastroenterol. 2012;47:678-685. [PMID: 22350698 DOI: 10.1007/s00535-012-0540-0] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
135 Wang R, Zheng-Pywell R, Chen HA, Bibb JA, Chen H, Rose JB. Management of Gastrointestinal Neuroendocrine Tumors. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419884058. [PMID: 31695546 DOI: 10.1177/1179551419884058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
136 Shen C, Chen H, Chen H, Yin Y, Han L, Chen J, Tang S, Yin X, Zhou Z, Zhang B, Chen Z. Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience. BMC Gastroenterol 2016;16:111. [PMID: 27613657 DOI: 10.1186/s12876-016-0505-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
137 Mayo SC, Herman JM, Cosgrove D, Bhagat N, Kamel I, Geschwind JF, Pawlik TM. Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies. J Am Coll Surg 2013;216:123-34. [PMID: 23063263 DOI: 10.1016/j.jamcollsurg.2012.08.027] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
138 Haider M, Jiang BG, Parker JA, Bullock AJ, Goehler A, Tsai LL. Use of MRI and Ga-68 DOTATATE for the detection of neuroendocrine liver metastases. Abdom Radiol (NY) 2021. [PMID: 34757459 DOI: 10.1007/s00261-021-03341-z] [Reference Citation Analysis]
139 Folkert IW, Hernandez P, Roses RE. Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas. World J Gastroenterol 2016; 22(11): 3105-3116 [PMID: 27003988 DOI: 10.3748/wjg.v22.i11.3105] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
140 Riechelmann RP, Weschenfelder RF, Costa FP, Andrade AC, Osvaldt AB, Quidute AR, Dos Santos A, Hoff AA, Gumz B, Buchpiguel C, Vilhena Pereira BS, Lourenço Junior DM, da Rocha Filho DR, Fonseca EA, Riello Mello EL, Makdissi FF, Waechter FL, Carnevale FC, Coura-Filho GB, de Paulo GA, Girotto GC, Neto JE, Glasberg J, Casali-da-Rocha JC, Rego JF, de Meirelles LR, Hajjar L, Menezes M, Bronstein MD, Sapienza MT, Fragoso MC, Pereira MA, Barros M, Forones NM, do Amaral PC, de Medeiros RS, Araujo RL, Bezerra RO, Peixoto RD, Aguiar S Jr, Ribeiro U Jr, Pfiffer T, Hoff PM, Coutinho AK. Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group. Ecancermedicalscience 2017;11:716. [PMID: 28194228 DOI: 10.3332/ecancer.2017.716] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
141 Chiorean L, Bartos A, Pelau D, Iancu D, Ciuleanu T, Buiga R, Oancea I, Mangrau A, Iancu C, Badea R. Neuroendocrine tumor of gallbladder with liver and retroperitoneal metastases and a good response to the chemotherapeutical treatment. J Med Ultrason (2001) 2015;42:271-6. [PMID: 26576584 DOI: 10.1007/s10396-014-0585-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
142 Lewis MA, Hobday TJ. Treatment of neuroendocrine tumor liver metastases. Int J Hepatol 2012;2012:973946. [PMID: 23227348 DOI: 10.1155/2012/973946] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
143 Pu N, Habib JR, Bejjani M, Yin H, Nagai M, Chen J, Kinny-Köster B, Chen Q, Zhang J, Yu J, Wu W, Lou W. The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study. Ann Transl Med 2021;9:329. [PMID: 33708956 DOI: 10.21037/atm-20-5348] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
144 Mehrvarz Sarshekeh A, Halperin DM, Dasari A. Update on management of midgut neuroendocrine tumors. Int J Endocr Oncol 2016;3:175-89. [PMID: 27347369 DOI: 10.2217/ije-2015-0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
145 Sartori S, Bianchi L, Di Vece F, Tombesi P. Liver-directed therapies for liver metastases from neuroendocrine neoplasms: Can laser ablation play any role? World J Gastroenterol 2020; 26(23): 3118-3125 [PMID: 32684730 DOI: 10.3748/wjg.v26.i23.3118] [Reference Citation Analysis]
146 Nagata K, Tajiri K, Shimada S, Ando T, Hosokawa A, Matsui K, Imura J, Sugiyama T. Rectal Neuroendocrine Tumor G1 with a Solitary Hepatic Metastatic Lesion. Intern Med 2017;56:289-93. [PMID: 28154272 DOI: 10.2169/internalmedicine.56.7523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
147 Gangi A, Howe JR. The Landmark Series: Neuroendocrine Tumor Liver Metastases. Ann Surg Oncol 2020;27:3270-80. [PMID: 32632880 DOI: 10.1245/s10434-020-08787-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
148 Woodside KJ, Townsend CM, Mark Evers B. Current management of gastrointestinal carcinoid tumors. J Gastrointest Surg. 2004;8:742-756. [PMID: 15358337 DOI: 10.1016/j.gassur.2004.04.010] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
149 Mathur A, Gorden P, Libutti SK. Insulinoma. Surg Clin North Am. 2009;89:1105-1121. [PMID: 19836487 DOI: 10.1016/j.suc.2009.06.009] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 4.8] [Reference Citation Analysis]
150 Cloyd JM, Wiseman JT, Pawlik TM. Surgical management of pancreatic neuroendocrine liver metastases. J Gastrointest Oncol 2020;11:590-600. [PMID: 32655938 DOI: 10.21037/jgo.2019.11.02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
151 Ambe CM, Nguyen P, Centeno BA, Choi J, Strosberg J, Kvols L, Hodul P, Hoffe S, Malafa MP. Multimodality Management of "Borderline Resectable" Pancreatic Neuroendocrine Tumors: Report of a Single-Institution Experience. Cancer Control. 2017;24:1073274817729076. [PMID: 28975822 DOI: 10.1177/1073274817729076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
152 Kulik U, Lehner F, Bektas H, Klempnauer J. Liver Resection for Non-Colorectal Liver Metastases - Standards and Extended Indications. Viszeralmedizin 2015;31:394-8. [PMID: 26889142 DOI: 10.1159/000439419] [Reference Citation Analysis]
153 Poncet G, Faucheron JL, Walter T. Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel. World J Gastroenterol 2010; 16(14): 1696-1706 [PMID: 20380000 DOI: 10.3748/wjg.v16.i14.1696] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
154 Hung JS, Chang MC, Lee PH, Tien YW. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? World J Surg. 2007;31:2392-2397. [PMID: 17960455 DOI: 10.1007/s00268-007-9264-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
155 Saeed A, Buell JF, Kandil E. Surgical treatment of liver metastases in patients with neuroendocrine tumors. Ann Transl Med 2013;1:6. [PMID: 25332951 DOI: 10.3978/j.issn.2305-5839.2013.01.08] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
156 Orcutt ST, Artinyan A, Li LT, Silberfein EJ, Berger DH, Albo D, Anaya DA. Postoperative mortality and need for transitional care following liver resection for metastatic disease in elderly patients: a population-level analysis of 4026 patients. HPB (Oxford) 2012;14:863-70. [PMID: 23134189 DOI: 10.1111/j.1477-2574.2012.00577.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]